API maker Hovione moves into particle design

Portuguese API maker Hovione has invested in crystal design and particle size reduction to the nanoscale size and amorphose solid dispersion so it can offer those capabilities for the lab or commercial scale-up. The company tells in-PharmaTechnologist that it was hearing from customers that they needed the capability to handle "highly potent compounds." The publication points out that Hovione has been putting attention on solubility solutions. Last year, it struck a deal with Particle Sciences ($PSI) that allowed it to offer scale-up manufacturing services for solubilization processes developed by PSI. Story | More

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.